Tango Therapeutics Inc（TNGX）财务数据TNGXTango Therapeutics Inc

Evaluating the bottom line, Tango Therapeutics, Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -21.34%, provide a clear picture of how effectively TNGX converts its operational activities into shareholder value.

In the context of the broader market, TNGX competes directly with industry leaders such as ABCL and RLAY. With a market capitalization of $3.74B, it holds a significant position in the sector. When comparing efficiency, TNGX's gross margin of N/A stands against ABCL's 100.00% and RLAY's 100.00%. Such benchmarking helps identify whether Tango Therapeutics, Inc. is trading at a premium or discount relative to its financial performance.

Tango Therapeutics has demonstrated strong revenue growth, particularly in Q3 2025 with total revenue reaching $53.81 million. However, it has also faced significant net losses, with a net income of -$55.34 million in Q2 2026. The gross margin remains strong at 100% in recent quarters, but future earnings are uncertain as they project zero revenue in upcoming quarters.